Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Caris Life Sciences, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$23.05-3.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Caris sells cancer tissue and blood tests to help doctors choose treatments, and provides molecular research services to drug companies.
Company outlook: revenue of $1B to $1.1B for Fiscal year 2026 — up 28.7% on a year earlier